Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Cancers | Free Full-Text | Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Studiehistorikk - Phase1
First-in-human Phase I “Basket” Study of Debio 1347 (CH5183284), a Novel FGFR Inhibitor in Patients with FGFR Genomically
Table of Contents page: Annals of Oncology
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma - ScienceDirect
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Life | Free Full-Text | Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Debio 1347-201 – Phase II basket trial in solid tumors harboring a fusion of FGFR1-3
PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
PDF) New clinical trial designs in the era of Precision Medicine
Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Frontiers | Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
